Inhibrx Biosciences (INBX) Non Operating Income (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Non Operating Income for 3 consecutive years, with -$1.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Non Operating Income fell 192.63% year-over-year to -$1.9 million; the TTM figure through Dec 2025 stood at -$5.0 million (down 100.25% YoY), while the FY2025 annual figure was -$5.0 million, down 100.25% from the prior year.
• Non Operating Income declined to -$1.9 million in Q4 2025 per INBX's latest filing, from -$1.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at $2.0 billion in Q2 2024 and bottomed at -$6.0 million in Q3 2023.
• Historically, Non Operating Income has averaged $181.7 million across 3 years, with a median of -$1.4 million in 2025.
• Annual changes were most pronounced in 2024 — Non Operating Income surged 35469.85% — and 2025, when it plunged 192.63%.
• Inhibrx Biosciences' Non Operating Income stood at -$3.7 million in 2023, then soared by 155.98% to $2.1 million in 2024, then plunged by 192.63% to -$1.9 million in 2025.
• Business Quant data shows INBX's Non Operating Income at -$1.9 million in Q4 2025, -$1.4 million in Q3 2025, and -$1.3 million in Q2 2025.